Hypoxia is a known adverse factor in cancer treatment, able to activate signaling pathways MAPK and PI3K / Akt / mTOR, the two major pathways involved in the process of angiogenesis which is regulated by numerous factors, the most significant is the Hypoxia-Inducible Factor - 1 (HIF-1) and Vascular Endothelial Growth Factor (VEGF). The transcription factor HIF-1± is the major regulator of pathophysiological response of cells to conditions of hypoxia, capable of activating transcription of the VEGF, which promotes angiogenesis through its ability to stimulate the growth, migration and invasion of endothelial cells. Therefore, many studies have focused on developing treatment strategies that may be involved in signaling pathways PI3K-MAPK/Akt/mTOR in attempt to inhibit tumor progression. Some studies have shown that treatment with metformin inhibits cell growth through signaling pathway of MAPK/Akt/mTOR and that LY294002 has anti-angiogenic features, able to block the PI3K/Akt signaling pathway in hypoxia, decreasing the release of factors growth such as VEGF. However, little is known about the influence of treatment with metformin in combination with LY294002 in angiogenesis, particularly in mammary tumor. The objective of this study is to evaluate treatment with metformin and LY294002 in tumor angiogenesis as a therapeutic strategy in mammary tumors, an in vitro and in vivo study. The gene and protein expression of HIF-1± and VEGF will be verified by qPCR and immunohistochemistry, respectively. The cell distribution in the phases of the cell cycle and apoptosis by flow cytometry, the expression of proteins involved in signaling pathways of MAPK, PI3K / Akt / mTOR by Antibody Array and the angiogenesis by immunostaining of endothelial cell marker CD31. The results obtained may provide evidence for the use of metformin with or without the inhibitor LY294002 as therapeutic agents in mammary tumor.
News published in Agência FAPESP Newsletter about the scholarship: